Jonathan Friedberg, Director of the Wilmot Cancer Institute, shared a post on X:
“PROs vs clinician-reported adverse events in the POLARIX study: we are insufficiently capturing patient experience with conventional toxicity assessments. Great collaboration with Dr. Carrie Thompson, Mayo Clinic, Wilmot Cancer.”
Title: PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
Journal: Blood
Authors: Carrie Thompson, Marek Trněný, Franck Morschhauser, Gilles A. Salles, Patrick M. M. Reagan, Mark Hertzberg, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won Seog Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Singh, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman, Neha Mehta-Shah, Christopher R. Flowers, Hervé Tilly, Neil Chua, Olivier Casasnovas, Fiona Miall, Tae Min Min Kim, Xavier Cheng-Hong Tsai, Sunita D. Nasta, Seung Tae Lee, and Jonathan W. Friedberg
More from Jonathan Friedberg on OncoDaily.